← All diseases Cancer

Liver cancer

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the most robust evidence (78)Meta-analysis (34)Treatment guideline (5)Systematic review (18)Randomized trial (14)Phase 3 study (7)Clinical trial (608)Review article (448)Early study (phase 1 or 2) (26)Laboratory or animal research (164)Case report (110)Commentary or editorial (69)Retracted publication (8)Concerns have been raised (1) Studies currently recruiting participants only (41)

Filter

Publications and studies (3377)

• Analysis of Immune-Related Adverse Events of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study. (2023/12/21) ♡
• Up-regulation of SLC7A11/xct creates a vulnerability to selenocystin-induced cytotoxicity. (2023/12/20) ♡
• Geriatric prognostic scoring system predicts survival after hepatectomy for elderly patients with liver cancer. (2023/12/19) ♡
• Artichoke (Cynara scolymus L.) water extract alleviates palmitate-induced insulin resistance in HepG2 hepatocytes via the activation of IRS1/PI3K/Akt/Foxo1 and GSK-3β signaling pathway. (2023/12/15) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Protocol for generation of humanized HCC mouse model and cancer-driver mutations using CRISPR-Cas9. (2023/12/15) ♡
• Cryptocaryone induces apoptosis in human hepatocellular carcinoma cells by inhibiting aerobic glycolysis through Akt and c-SRC signaling pathways. (2023/12/15) ♡
• RNA binding motif protein 43 (RBM43) suppresses hepatocellular carcinoma metastasis by regulating Slug mRNA stability. (2023/12/14) ♡
• Role of contrast-enhanced ultrasound for differentiation of benign vs. malignant portal vein thrombosis in hepatocellular carcinoma - A systematic review a meta-analysis. (2023/12/10) ♡
• Identification of a β-Carboline Alkaloid from Chemoselectively Derived Vanilla Bean Extract and Its Prevention of Lipid Droplet Accumulation in Human Hepatocytes (HepG2). (2023/12/09) ♡
• α-fetoprotein, α-fetoprotein-L3, and DES-γ Carboxy Prothrombin Stratify Hepatocellular Carcinoma Treatment Response and Progression Risk. (2023/12/07) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. MAPL loses dysregulates bile and liver metabolism in mice. (2023/12/06) ♡
• Exploring the mechanism of Jianpi Huatan recipe in protecting hepatocellular carcinoma based on network pharmacology. (2023/12/05) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Hepatocyte CHRNA4 mediates the MASH-promotive effects of immune cell-produced acetylcholine and smoking exposure in mice and humans. (2023/12/05) ♡
• A personalized approach for tumour biopsy in hepatocellular carcinoma. (2023/12/03) ♡
• Mechanisms of dihydromyricetin against hepatocellular carcinoma elucidated by network pharmacology combined with experimental validation. (2023/12/01) ♡
• Wogonin inhibits hepatoma cell proliferation by targeting miR-27b-5p/YWhaz axis. (2023/12/01) ♡
• Preoperative Weight Loss Program for Hepatocellular Carcinoma Patients with High Body Mass Index in Hepatectomy. (2023/12/01) ♡
• Elongation of very long chain fatty acids-3 (Elovl3) is activated by ZHX2 and is a regulator of cell cycle progression. (2023/12/01) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Cancers Attributable to Infections in the US in 2017: A Meta-Analysis. (2023/12/01) ♡
• Hepatocellular loss of mTOR aggravates tumor burden in nonalcoholic steatohepatitis-related HCC. (2023/12/01) ♡
• Portal-hypertension features are associated with ascites occurrence and survival in patients with hepatocellular carcinoma treated by external radiotherapy. (2023/12/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Efficacy and outcome of molecular targeted therapies in elderly patients with hepatocellular carcinoma: Relative dose intensity associated with overall survival. (2023/12/01) ♡
• A novel nomogram for prognosis stratification in salvage liver transplantation: a national-wide study with propensity score matching analysis in China. (2023/12/01) ♡
• Laparoscopic anatomical versus non-anatomical liver resection for hepatocellular carcinoma in the posterosuperior segments: a propensity score matched analysis. (2023/12/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Proton beam therapy for downstaging hepatocellular carcinoma with lobar portal vein tumor thrombosis to living donor liver transplantation. (2023/12/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Metabolic dysfunction-associated fatty liver disease and hepatocellular carcinoma: present and future. (2023/12/01) ♡
• Efficacy and safety of subsequent radiotherapy in patients with advanced-stage hepatocellular carcinoma treated with immune checkpoint inhibitors. (2023/12/01) ♡
• Cyclin D1 extensively reprograms metabolism to support biosynthetic pathways in hepatocytes. (2023/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Practice-changing clinical trials in radiation oncology for gastrointestinal malignancies in 2021-2023. (2023/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Mixed Hepatocellular-Neuroendocrine Carcinoma: A Case Report and Literature Review. (2023/12/01) ♡
• Co-incidence of COVID-19 and hepatocellular carcinoma during pregnancy: Double punches to disease severity and mortality? (2023/12/01) ♡
• Thrombospondin-2 as a potential noninvasive biomarker of hepatocyte injury but not liver fibrosis in children with MAFLD: A preliminary study. (2023/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The role of microRNAs in hepatocellular carcinoma: Therapeutic targeting of tumor suppressor and oncogenic genes. (2023/12/01) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Leukotriene B4 receptor 1 (BLT1) does not mediate disease progression in a mouse model of liver fibrosis. (2023/11/28) ♡
• AKR1B1 drives hyperglycemia-induced metabolic reprogramming in MASLD-associated hepatocellular carcinoma. (2023/11/28) ♡
• A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial). (2023/11/28) ♡
• Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III iMBrave150 Study. (2023/11/28) ♡
• Correlation between preoperative systemic immune inflammation index, nutritional risk index, and prognosis of radical resection of liver cancer. (2023/11/27) ♡
• The expression of VEGF and cyclin D1/EGFR in common primary liver carcinomas in Egypt: an immunohistochemical study. (2023/11/27) ♡
• [Alcoholic liver disease - 2023]. (2023/11/26) ♡
• CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma. (2023/11/24) ♡
• COVID-19 Pandemic Impact on Diagnosis, Internship, and Treatment of Hepatocellular Carcinoma in the United States. (2023/11/23) ♡
• Integrating single-cell and spatial transcriptomics to elucidate the crosstalk between cancer-associated fibroblasts and cancer cells in hepatocellular carcinoma with spleen deficiency syndrome. (2023/11/22) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Time-restricted feeding ameliorates MCDD-induced steatohepatitis in mice. (2023/11/17) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. The application of arsenic trioxide in cancer: An umbrella review of meta-analyses based on randomized controlled trials. (2023/11/15) ♡
• Integrated investigation and experimental validation of PPARG as an oncogenic driver: implications for prognostic assessment and therapeutic targeting in hepatocellular carcinoma. (2023/11/15) ♡
• Loss of cis-PTase function in the liver promotes a highly penetrant form of fatty liver disease that rapidly transitions to hepatocellular carcinoma. (2023/11/15) ♡
• Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment-related toxicity in hepatocellular carcinoma. (2023/11/15) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Unusual sites of hepatocellular carcinoma metastasis: Case report. (2023/11/14) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy? (2023/11/13) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.